{"id":179740,"date":"2026-02-05T23:05:13","date_gmt":"2026-02-06T04:05:13","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179740"},"modified":"2026-02-05T23:05:13","modified_gmt":"2026-02-06T04:05:13","slug":"sequent-scientific-viyash-reports-higher-revenue-and-margins-in-first-merged-entity-quarter","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sequent-scientific-viyash-reports-higher-revenue-and-margins-in-first-merged-entity-quarter\/","title":{"rendered":"Sequent Scientific (Viyash) reports higher revenue and margins in first merged-entity quarter"},"content":{"rendered":"\n

Sequent Scientific Limited (now Viyash Scientific Limited) (BSE: 512529 \/ NSE: SEQUENT)<\/strong> reported higher revenue and profitability in the quarter ended December 31, 2025, reflecting growth in its formulations, APIs and CDMO businesses in the first quarter reported on a combined post-merger basis.<\/p>\n\n\n\n

For Q3 FY26, consolidated revenue rose 10.9% year-on-year to \u20b98,584 million, while EBITDA (excluding ESOP costs) increased 64.4% to \u20b91,854 million. Profit after tax rose 15.5% to \u20b9485 million, including merger-related exceptional costs.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Business overview<\/strong><\/h2>\n\n\n\n

Sequent Scientific (renamed Viyash Scientific Limited) operates across Formulations, Active Pharmaceutical Ingredients (APIs), and CDMO services<\/strong> for both human and animal health. The company has manufacturing, R&D and distribution operations in India, Spain, Brazil, Turkey and the United States, serving customers in over 100 countries.<\/p>\n\n\n\n

The company is positioned among the top 25 animal health companies globally, with approvals from international regulators including USFDA, EU-GMP, WHO and TGA.<\/p>\n\n\n\n

Financial performance \u2014 Q3 FY26<\/strong><\/h2>\n\n\n\n

Revenue in Q3 FY26 increased to \u20b98,584 million from \u20b97,740 million in Q3 FY25. EBITDA (excluding ESOP costs) rose to \u20b91,854 million from \u20b91,127 million, lifting the EBITDA margin to 21.6% from 14.6% a year earlier.<\/p>\n\n\n\n

Profit after tax stood at \u20b9485 million, compared with \u20b9420 million in Q3 FY25, after accounting for \u20b9413 million of merger-related exceptional costs and a one-time MAT credit reversal of \u20b977 million.<\/p>\n\n\n\n

Nine-month performance (9M FY26)<\/strong><\/h2>\n\n\n\n

For the nine months ended December 2025, revenue increased 11.9% to \u20b925,004 million from \u20b922,345 million in 9M FY25. EBITDA (excluding ESOP costs) rose 58% to \u20b95,024 million, with margin improving to 20.1% from 14.2%.<\/p>\n\n\n\n

Profit after tax for 9M FY26 increased sharply to \u20b91,583 million, compared with \u20b9480 million in the prior year period.<\/p>\n\n\n\n

Merger and strategic developments<\/strong><\/h2>\n\n\n\n

Q3 FY26 marked the first quarter in which results of the merged entity were presented on a combined basis. Management stated that the merger is beginning to generate benefits across R&D, manufacturing and front-end operations.<\/p>\n\n\n\n

The company indicated plans to strengthen its Companion Animal portfolio<\/strong> and expand its CDMO services<\/strong> offering.<\/p>\n\n\n\n

Balance sheet and debt position<\/strong><\/h2>\n\n\n\n

The company reported pre-closure of high-cost debt during the period, with net debt to EBITDA at 0.38x, reflecting an improvement in leverage metrics.<\/p>\n\n\n\n

Risks and constraints<\/strong><\/h2>\n\n\n\n

The press release notes that forward-looking statements are subject to risks including government actions, economic conditions, technological risks and other factors that could cause actual results to differ materially from expectations.<\/p>\n\n\n\n

Management commentary<\/strong><\/h2>\n\n\n\n

The Managing Director and Group CEO stated that revenue, margins and profitability continued to show growth due to new product introductions, cost improvements and synergies across business units, and that the company is positioned to capture market opportunities over the next three to five years.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sequent Scientific Limited (now Viyash Scientific Limited) (BSE: 512529 \/ NSE: SEQUENT) reported higher revenue and profitability in the quarter ended December 31, 2025, reflecting growth in its formulations, APIs and CDMO businesses in the first quarter reported on a combined post-merger basis. For Q3 FY26, consolidated revenue rose 10.9% year-on-year to \u20b98,584 million, while […]<\/p>\n","protected":false},"author":2390,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,1941,5747,5],"tags":[15847,15852,15845,15854,14580,15851,15855,15850,15853,14559,15844,15846,15849,15843,15848],"class_list":["post-179740","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-stock-analysis","category-healthcare-stocks","category-latest","tag-animal-health-pharma","tag-apis-manufacturing","tag-bse-512529","tag-cdmo-services","tag-corporate-earnings-india","tag-formulations-business","tag-merger-integration","tag-nse-sequent","tag-pharmaceutical-industry-india","tag-quarterly-results-india","tag-sequent-earnings","tag-sequent-q3-fy26","tag-sequent-results","tag-sequent-scientific","tag-viyash-scientific"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":161213,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-ltd-q4fy24-1-fall-in-revenue\/","url_meta":{"origin":179740,"position":0},"title":"Sequent Scientific Ltd Q4FY24; 1% fall in Revenue","author":"Chirag Gupta","date":"May 15, 2024","format":false,"excerpt":"Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries. Financial Results: Sequent Scientific Ltd reported\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-116.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164595,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-ltd-q1fy24-2-fall-in-revenue\/","url_meta":{"origin":179740,"position":1},"title":"Sequent Scientific Ltd Q1FY24; 2% fall in Revenue","author":"Chirag Gupta","date":"October 1, 2024","format":false,"excerpt":"Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries. Financial Results: Sequent Scientific Ltd reported\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":175165,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-sequent-q2-2025-earnings-call-transcript\/","url_meta":{"origin":179740,"position":2},"title":"Sequent Scientific Limited (SEQUENT) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Sequent Scientific Limited (NSE: SEQUENT) Q2 2025 Earnings Call dated Nov. 14, 2024 Corporate Participants: Abhishek Singhal \u2014 Head of Investor Relations Rajaram Narayanan \u2014 Managing Director Saurav Bhala \u2014 Chief Financial Officer Hari Babu \u2014 Whole Time Director and CEO Analysts: Hrithika \u2014 Analyst Nikhil Shetty \u2014 Analyst Bharat\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":155837,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-ltd-q2fy24-2-rise-in-revenue\/","url_meta":{"origin":179740,"position":3},"title":"Sequent Scientific Ltd Q2FY24; 2% rise in Revenue","author":"Chirag Gupta","date":"November 6, 2023","format":false,"excerpt":"Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries. Financial Results: Sequent Scientific Ltd reported\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-76.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143225,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":179740,"position":4},"title":"Sequent Scientific Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 9, 2023","format":false,"excerpt":"Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API business, the company crossed the INR100 crore revenue mark in 3Q23, with a 16.5% sequential quarter-on-quarter growth. Q&A Highlights: [00:17:59] Rahul Maheshwari enquired about the growth rate targeted for Europe\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127593,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":179740,"position":5},"title":"Sequent Scientific Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 15, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=iqM668J91yY Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY22 Earnings Concall Management Update: SEQUENT saw significant improvement in the API order book and dispatches in the quarter that were almost at 3Q21 levels, which was the best ever quarter in terms of the reported API numbers. Q&A Highlights: Sanam\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2390"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179740"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179740\/revisions"}],"predecessor-version":[{"id":179742,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179740\/revisions\/179742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}